Abigail Brooks, MA

This clinical quiz will test your knowledge of the 2023 American Association for the Study of Liver Diseases/Infectious Diseases Society of America Hepatitis C guideline.

Results suggest chronic hepatitis B virus is globally underassessed and undertreated, especially among women and Asian minorities in the West.

Sofosbuvir/velpatasvir/voxilaprevir rescue therapy was safe and effective, and SVR did not significantly differ based on genotype, cirrhosis, or first-line therapy.

Findings suggest the potential prognostic value of time-averaged serum uric acid for predicting disease progression in IgAN.

Findings suggest unstable housing may inhibit direct-acting antiviral treatment initiation in PWID with unstable housing compared to those with stable housing.

Proteinuria < 1 g/d is the current treatment target, but findings suggest patients with uACR between 0.3 and 1.0 g/g face a substantial risk of adverse kidney outcomes.

Vitamin D concentration was significant in chronic hepatitis B virus but not hepatitis C virus infection, suggesting its potential impact on immune response.

Results showed the prevalence and treatment patterns for IgAN in select Asian Pacific countries and regions were not commonly available.

Results showed 46.45 and 72.74% increases in the global incidences of acute infection and HCV-related cirrhosis, respectively, in reproductive-age women.

Findings showed the light microscopy pattern of glomerular injury and the intensity of mesangial C3 deposition may refine the histological assessment of IgAN.

Findings suggest metformin and statins have a potective effect against HCC in patients with HCV who fail antiviral therapy.

This month in review highlights top coverage of the latest news in nephrology, ranging from new clinical trial data in IgAN to research about kidney disease management.

Urinary cytokines GDF-15, IL-6, and EGF significantly strengthened the predictability of IgAN prognosis and may be viable biomarker candidates for disease progression.

The April 2024 month in review features HCPLive’s top coverage of resmetirom, other key hepatic pipeline updates, and recent research about hepatitis C virus.

In the first segment of this HCPLive special report, experts discuss the stigma surrounding alcohol use disorder and alcohol-associated liver disease.

Findings highlight an increase in hospitalization among pregnant patients with HCV, further describing age’s impact on mortality, cirrhosis, preterm births, and stillbirths.

This April 2024 month in review highlights World IBS Day, updates in the gastroenterology pipeline, ACP Internal Medicine meeting coverage, and recent IBD research.

Barratt explained findings from the phase 2b ORIGIN trial of atacicept and how it compares to current standard therapies in IgAN and other agents in the pipeline.

KDpredict uses age, sex, eGFR, and albuminuria to calculate 1-5 year risk of kidney failure and death in chronic kidney disease, outperforming the kidney failure risk equation.

Results showed a negative correlation between serum Gd-IgA1 and kidney function but found no association with several validated IgAN prognostic risk factors.

Tenofovir disoproxil fumarate was safe and effective for preventing mother-to-child transmission of HBV, but discontinuation was linked to postpartum hepatitis flares.

Solomon discusses the health care system’s role in mitigating climate change and how health care professionals can help protect and inform their patients.

Positive topline results showed treatment response consistent with NefIgArd findings, regardless of whether participants had previously been treated with Nefecon or placebo.

Solomon explains how the health care system contributes to climate change and the direct health impacts seen as a result, based on her session at ACP.

Branch provides an overview of the use of dual antiplatelet therapy and anticoagulants based on his session at the ACP Internal Medicine meeting.

Shah discusses the prevalence of psychiatric illness among hospitalized patients and highlights key considerations for their management from her session at ACP.

Nahas reviews key highlights from her session at ACP, emphasizing the importance of reviewing patient history and considering what other factors may be causing headaches.

Branch discusses key takeaways from his session at ACP and guideline recommendations for primary and secondary prevention of cardiovascular disease.

Contrary to previous research, findings point to similar decreases in weight and improvements in glucose homeostasis between time-restricted eating and usual eating pattern groups.

Markland discusses the use of anticholinergics, beta 3-agonists, and nonpharmacologic treatments for urge urinary incontinence, based on her session at ACP.